



TITLE:

# Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer.

AUTHOR(S):

Kim, Young Hak; Yoh, Kiyotaka; Niho, Seiji; Goto, Koichi; Ohmatsu, Hironobu; Kubota, Kaoru; Nishiwaki, Yutaka

---

CITATION:

Kim, Young Hak ...[et al]. Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer.. Respiratory medicine 2010, 104(3): 434-439

ISSUE DATE:

2010-03

URL:

<http://hdl.handle.net/2433/101564>

RIGHT:

Crown Copyright c 2009.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.

## Original Article

# Trends in chemotherapy for elderly patients with advanced non–small-cell lung cancer

**Young Hak Kim MD<sup>1,2</sup>, Kiyotaka Yoh MD<sup>1</sup>, Seiji Niho MD, PhD<sup>1</sup>, Koichi Goto MD,  
PhD<sup>1</sup>, Hironobu Ohmatsu MD<sup>1</sup>, Kaoru Kubota MD, PhD<sup>1</sup>, Yutaka Nishiwaki MD<sup>1</sup>**

<sup>1</sup>Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1

Kashiwanoha, Kashiwa, Chiba 277-8577, Japan

<sup>2</sup> Department of Respiratory Medicine, Kyoto University Hospital, 54

Shogoin-Kawaharacho, sakyo-ku, Kyoto 606-8507, Japan

**Correspondence:** Young Hak Kim; E-mail: [ekim@kuhp.kyoto-u.ac.jp](mailto:ekim@kuhp.kyoto-u.ac.jp); Address:

Department of Respiratory Medicine, Kyoto University Hospital, 54

Shogoin-Kawaharacho, sakyo-ku, Kyoto 606-8507, Japan. Phone: +81-75-751-3830;

Fax: +81-75-751-4643

This manuscript includes 18 text pages, 6 tables, and 1 figure.

**Running Title: Chemotherapy for NSCLC in the elderly**

**Keywords: non-small-cell lung cancer, elderly, chemotherapy, third-generation,  
second-line**

## ABSTRACT

**BACKGROUND.** In approximately the year 2000, the results of a number of important studies of non–small-cell lung cancer (NSCLC) were published.

**METHODS.** Between July 1992 and December 2003, 223 patients with NSCLC aged  $\geq 70$  years received chemotherapy alone as their initial treatment at the National Cancer Center Hospital East. These patients were divided into 2 groups: those that began treatment between 1992 and 1999 (group A) and between 2000 and 2003 (group B). The details of chemotherapy regimens and outcomes were compared.

**RESULTS.** In group A, 83% of patients received platinum-based chemotherapy, two-thirds of these regimens comprised platinum plus second-generation combination chemotherapy. In contrast, although 55% of patients received platinum-based chemotherapy in group B, 41% of patients received non-platinum-based chemotherapy. Among patients in group B, performance status was significantly associated with the selection of platinum-based or non-platinum-based chemotherapy; age was marginally associated with this selection. Median survival time (MST), 1-year survival rate, and 2 year-survival rate were 6.7 months, 14%, and 7%, respectively, in group A, and 8.1 months, 35%, and 20% in group B ( $p = 0.0109$ ). Multivariate analysis revealed that clinical stage and administration of salvage chemotherapy were independent prognostic

factors.

**CONCLUSIONS.** In and after the year 2000, chemotherapy regimens changed greatly and survival of elderly patients significantly improved in our institute, and this improvement appears to be attributable mostly to the effect of salvage chemotherapy. These results suggest that even elderly patients should be offered salvage chemotherapy regardless of age, if possible.

## INTRODUCTION

Lung cancer is the leading cause of cancer-related death in many industrialized countries. Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of all lung cancers, and the majority of patients have metastatic disease at the time of diagnosis<sup>1</sup>. Previous data indicate that more than 50% of advanced NSCLC are diagnosed in patients aged  $\geq 65$  years and about 30% to 40% are diagnosed in patients  $\geq 70$  years of age<sup>2</sup>. NSCLC can therefore be regarded as a disease of the elderly, and the proportion of older adults among NSCLC patients is expected to progressively increase due to the aging of the populations of most developed countries.

Platinum-based combination chemotherapy improves survival and quality-of-life (QOL) in patients with advanced NSCLC, and is now widely accepted as the standard in chemotherapy<sup>3, 4</sup>. However, platinum-based chemotherapy is often contraindicated in elderly patients because of patient deficits in functional status and organ function. In addition, elderly patients have approximately twice as many comorbidities as the general population<sup>5, 6</sup>. Past studies on the effect of age on treatment choices for advanced NSCLC have revealed that elderly patients were less likely to receive active treatments<sup>7-9</sup>. Until recently, clinical trials for NSCLC have not specifically examined the importance of chronological age or the desirability of an

upper age limit for treatment. Indeed, it has been reported that elderly patients are under-represented in those trials. In fact, according to a survey conducted by the Southwest Oncology Group, only 39% of patients enrolled in lung cancer trials between 1993 and 1996 were older than age 65, even though such patients represent 66% of the overall cancer patient population<sup>10</sup>.

The lack of clinical data on elderly NSCLC patients encouraged physicians to carry out elderly-specific clinical trials. In the 1990s, third-generation cytotoxic agents, such as vinorelbine (VNR), gemcitabine, docetaxel (DOC), paclitaxel, and irinotecan, were developed, and single-agent chemotherapy regimens using these agents were investigated in many phase II trials. In 1999, the results of the first elderly-specific phase III trial comparing VNR to best supportive care were published<sup>11</sup>. In that study, a significant survival benefit was seen in patients receiving VNR. Furthermore, VNR was well tolerated and QOL scores were better in patients treated with VNR. Then, in 2000, 2 phase III trials revealed a survival benefit for DOC when used as second-line chemotherapy agent, which was the first evidence for the effectiveness of second-line chemotherapy for NSCLC<sup>12, 13</sup>. In addition, in 2002, as compared to other countries, approval for gefitinib, epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI), was granted early in Japan.

These results should have a significant impact on clinical practice relating to advanced NSCLC in the elderly. In this study, we reviewed data on chemotherapy regimens used in the treatment of elderly NSCLC patients at our institute, and compared regimens and patient outcomes before and after year 2000.



## MATERIALS AND METHODS

### Patients

Between July 1992 and December 2003, 223 NSCLC patients aged  $\geq 70$  years received chemotherapy alone as their initial treatment at the National Cancer Center Hospital East. These patients were divided into 2 groups: those that began treatment between 1992 and 1999 (group A) and those that began treatment between 2000 and 2003 (group B). Chemotherapy regimens and outcomes were then compared between groups. Group B patients were then subdivided into 2 groups—the platinum-based chemotherapy group and the non-platinum-based chemotherapy group—and the clinical factors responsible for treatment choice were then analyzed. In addition, Group B patients were subdivided into another two groups; EGFR-TKI treated group or not-treated group. All patient data were obtained from our database.

### Tumor evaluation and statistical analysis

Survival time was measured from the start of chemotherapy to either the time of death from any cause or the date patients were last known to be alive. The survival curve was estimated using the Kaplan-Meier method, and compared by using the log-rank test. Comparisons between individual clinical factors were performed using the  $\chi^2$  test.

Multivariate analysis was conducted according to the Cox proportional hazards model.

$P < 0.05$  was considered to denote statistical significance. All statistical analyses were performed using StatView, Version 5.0 (Abacus Concepts, Berkley, CA).

## RESULTS

### Patient characteristics

Patient characteristics are listed in Table 1. There were 74 patients in group A and 149 in group B. Median age was almost identical, but the proportion of patients aged  $\geq 75$  years was significantly higher in group B ( $p = 0.0182$ ). Other clinical factors, including sex, performance status (PS), tumor histology, disease stage, and smoking history, were not significantly different between the groups.

### First-line chemotherapy

Details of first-line chemotherapy are shown in Table 2. In group A, 83% of patients received platinum-based chemotherapy; two-thirds of these were platinum-based plus second-generation combination chemotherapy regimens. In group B by contrast, although 55% of patients received platinum-based chemotherapy, 41% received non-platinum-based chemotherapy and 4% received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). EGFR-TKI as first-line treatment was all clinical trial settings. In group B, second-generation agents were no longer used, and the most frequently administered third-generation single-agent chemotherapy was VNR.

## **Clinical factors influencing selection of platinum-based and non-platinum-based chemotherapy**

In group B, 143 patients (96%) received platinum-based or non-platinum-based chemotherapy; only 6 patients (4%) received EGFR-TKI. In order to determine the clinical factors that affected the selection of platinum-based and non-platinum-based chemotherapy, relevant clinical factors were individually compared between these 2 patient subgroups. As shown in Table 3, only PS significantly differed between groups: patients with a PS of 0 or 1 tended to receive platinum-based chemotherapy; those with a PS of 2 tended to receive non-platinum-based chemotherapy ( $p = 0.004$ ). Other clinical factors did not significantly differ between the groups; however, the proportion of patients aged  $\geq 75$  years was marginally higher in the non-platinum-based chemotherapy group ( $p = 0.0596$ ).

## **EGFR-TKI treatment**

In group B, 34 patients received EGFR-TKI treatment during entire treatment period, while no patients in group A. In group B, the proportion of patients who received EGFR-TKI was significantly higher in female, adenocarcinoma, and never-smoked patients (Table 4).

## Second-line chemotherapy and beyond

The characteristics of patients who underwent multiple-line chemotherapy are shown in Table 5. In group A, second-line chemotherapy was administered to only 4 patients (5%) and no patients underwent third-line chemotherapy. In group B by contrast, second-line and third-line chemotherapy was administered to 62 (42%) and 22 (15%) patients, respectively. DOC was the agent most frequently used in second-line chemotherapy; EGFR-TKI was the most common agent for third-line chemotherapy.

## Survival

Median survival time (MST) was 6.7 months in group A and 8.1 months in group B ( $p = 0.0109$ ). The 1-year-survival rate and 2-year-survival rate were 14% and 7%, respectively, in group A, and 35% and 20% in group B. Survival curves are shown in Figure 1. The relationships between clinical variables and survival are shown in Table 6. Univariate analysis revealed that female, stage  $\leq$ IIIB, never-smoker, EGFR-TKI treatment, and the administration of salvage chemotherapy were associated with better survival. However, multivariate analysis demonstrated that only clinical stage and the administration of salvage chemotherapy were independent prognostic factors.

## DISCUSSION

In approximately the year 2000, the results of large phase III trials of treatments for advanced NSCLC were published. The findings of these studies were of great importance in understanding how to treat elderly patients with NSCLC. In the present retrospective study, we attempted to evaluate the impact of those trials by reviewing the records of 223 patients aged  $\geq 70$  years who began chemotherapy between 1992 and 2003 at our institute and comparing treatment details between those who began chemotherapy between 1992 and 1999 (group A) and those who began treatment between 2000 and 2003 (group B).

As we anticipated, the proportion of patients who received non-platinum-based chemotherapy, with either 1 or 2 agents, was higher in group B; however, more than 50% of patients in group B still received platinum-based chemotherapy. We further investigated group B to determine what clinical factors were associated with the selection of platinum-based or non-platinum-based chemotherapy. The results were unsurprising: patients with a PS of 2 aged  $\geq 75$  tended to receive non-platinum-based chemotherapy. Several sub-group analyses from phase III trials indicated that, when PS was not impaired, platinum-based chemotherapy was equally safe and effective in patients aged over and under 70 years<sup>14-17</sup>. The first elderly-specific trial comparing

platinum-based and non-platinum-based chemotherapy regimens also indicated that patients aged 70 to 74 years might derive more benefit from platinum-based chemotherapy than from non-platinum -based chemotherapy<sup>18</sup>. However, it is unclear whether platinum-based chemotherapy is safe and effective for patients aged  $\geq 75$  years.

In the present study, the proportion of patients who received salvage chemotherapy was also higher in group B. While only 5% of patients received second-line chemotherapy in group A, 42% received second-line chemotherapy in group B. In 15% of patients in group B, third-line chemotherapy was also administered.

Overall survival time was significantly longer in group B, as compared with group A, and multivariate analysis revealed that clinical stage and the administration of salvage chemotherapy were independent prognostic factors. Between group A and B, the difference of clinical stage was not significant. Therefore, these results seem to be the effect of salvage chemotherapy and suggest that even elderly patients should be offered salvage chemotherapy regardless of age, if possible. To date, several agents, such as docetaxel, gefitinib, erlotinib, and pemetrexed, have been approved as salvage chemotherapy worldwide, including Japan<sup>19</sup>. Physicians should not miss a chance to offer these effective agents to elderly patients.

In conclusion, in our institute, chemotherapy regimens changed considerably after

the year 2000. In addition, survival time significantly improved after 2000, and this improvement appears to be attributable mostly to the effect of salvage chemotherapy.

### **Conflict of Interest Statement**

None of the authors have a conflict of interest to declare in relation to this work.



## REFERENCES

1. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? *Lung Cancer* 2002;38 Suppl 2:S45-50.
2. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. *J Clin Oncol* 2005;23(13):3125-37.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med* 2002;346(2):92-8.
4. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol* 2007;18(2):317-23.
5. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. *Chest* 2005;128(2):947-57.
6. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. *J Clin Oncol* 2007;25(14):1898-907.
7. Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. *Lung Cancer* 1995;13(3):235-52.
8. Brown JS, Eraut D, Trask C, Davison AG. Age and the treatment of lung cancer. *Thorax* 1996;51(6):564-8.
9. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? *Chest* 2000;117(5):1239-46.
10. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr., Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. *N Engl J Med* 1999;341(27):2061-7.
11. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. *J Natl Cancer Inst* 1999;91(1):66-72.
12. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol* 2000;18(10):2095-103.
13. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol* 2000;18(12):2354-62.

14. Kelly K, Giarritta S, Akerley W, et al. Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. *Proc Am Soc Clin Oncol* 2001;20:329a.
15. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. *J Natl Cancer Inst* 2002;94(3):173-81.
16. Langer CJ, Vangel J, Schiller DP, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (<70). *Proc Am Soc Clin Oncol* 2003;22:639a.
17. Goto K, Nishiwaki Y, Saijo N, et al. The Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC): A subgroup analysis in elderly patients. *Proc Am Soc Clin Oncol* 2006;24:7115a.
18. Tsukada H, Yokoyama A, Nishiwaki Y, et al. Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207. *Proc Am Soc Clin Oncol* 2007;25:7629a.
19. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. *Oncologist* 2008;13(Suppl1):28-36.

## Figure legends

Figure 1. Kaplan-Meier curve of overall survival in all patients ( $n = 232$ ). Median survival time, 1-year-survival rate, and 2-year-survival rate were 6.7 months, 14%, and 7%, respectively, in group A , and 8.1 months, 35%, and 20% in group B.




Fig. 1

**Table 1. Patient characteristics (n=223)**

	<b>Group A ('92-'99)</b>	<b>Group B ('00-'03)</b>
<b>No. of patients</b>	<b>74</b>	<b>149</b>
<b>Age</b>		
<b>Median</b>	<b>73</b>	<b>74</b>
<75	55 (75%)	86 (58%)
≥75	19 (25%)	63 (42%)
<b>Sex</b>		
Male	62 (84%)	115 (78%)
Female	12 (16%)	34 (22%)
<b>ECOG PS</b>		
0-1	69 (93%)	136 (91%)
2	5 (7%)	13 (9%)
<b>Histology</b>		
Ad	52 (70%)	84 (56%)
Non-Ad	22 (30%)	65 (44%)
<b>Stage</b>		
≤IIIb	25 (34%)	55 (37%)
IV	49 (66%)	94 (63%)
<b>Smoking history</b>		
Current/former	62 (84%)	119 (80%)
Never	12 (16%)	30 (20%)

ECOG, Eastern Clinical Oncology Group; PS, performance status

**Table 2. First-line chemotherapy**

	Group A ('92-'99)	Group B ('00-'03)
<b>Platinum based</b>		
Platinum + 2nd-generation	41 (56%)	0 (0%)
CDDP+VDS+MMC	26	0
CDDP+VDS	14	0
254S+VDS	1	0
Platinum + 3rd-generation	20 (27%)	83 (55%)
CDDP+VNR	3	44
CDDP+DOC	15	15
CBDCA+PTX	0	12
CDDP+VNR+GEM	0	5
CDDP+GEM	0	4
CDDP+CPT-11	2	3
<b>Non-platinum based</b>		
2nd-generation	3 (4%)	0 (0%)
ETP	3	0
3rd-generation (mono)	7 (10%)	29 (20%)
VNR	2	23
DOC	0	5
GEM	0	1
PTX	3	0
CPT-11	2	0
3rd-generation (doublet)	2 (3%)	31 (21%)
GEM+VNR	2	31
<b>EGFR-TKI</b>	0 (0%)	6 (4%)
Gefitinib	0	6

CDDP, cisplatin; VDS, vindesine; MMC, mitomycin C; 254S, nedaplatin; VNR, vinorelbine; DOC, docetaxel; CBDCA, carboplatin; PTX, paclitaxel; GEM, gemcitabine; CPT-11, irinotecan; ETP, etoposide

**Table 3. Patient characteristics of Group B (platinum vs non-platinum)**

	Platinum based	Non-platinum based	<i>P</i>
No. of patients	83	60	
Age			
Median	73	74	
<75	55 (66%)	28 (47%)	0.0596
≥75	30 (34%)	32 (53%)	
Sex			
Male	66 (80%)	47 (78%)	>0.9999
Female	17 (20%)	13 (22%)	
Performance status			
0-1	81 (98%)	50 (83%)	0.0040*
2	2 (2%)	10 (17%)	
Histology			
Ad	51 (61%)	29 (48%)	0.1283
Non-Ad	32 (39%)	31 (52%)	
Stage			
≤IIIb	33 (40%)	21 (35%)	0.6032
IV	50 (60%)	39 (65%)	
Smoking history			
Current/former	66 (80%)	49 (82%)	0.8326
Never	17 (20%)	11 (18%)	
Ad, adenocarcinoma			

**Table 4. Patient characteristics of Group B (EGFR-TKI treated vs not EGFR-TKI treated)**

	EGFR-TKI(+)	EGFR-TKI(-)
<b>No. of patients</b>	<b>34</b>	<b>115</b>
<b>Age</b>		
<b>Median</b>	<b>73</b>	<b>74</b>
<75	25 (74%)	61 (53%)
≥75	9 (26%)	54 (47%)
<b>Sex</b>		
<b>Male</b>	<b>19 (56%)</b>	<b>96 (83%)</b>
<b>Female</b>	<b>15 (44%)</b>	<b>19 (17%)</b>
<b>Performance status</b>		
<b>0-1</b>	<b>30 (88%)</b>	<b>106 (92%)</b>
<b>2</b>	<b>4 (12%)</b>	<b>9 (8%)</b>
<b>Histology</b>		
<b>Ad</b>	<b>27 (79%)</b>	<b>57 (50%)</b>
<b>Non-Ad</b>	<b>7 (21%)</b>	<b>58 (50%)</b>
<b>Stage</b>		
<b>≤IIIb</b>	<b>11 (32%)</b>	<b>44 (38%)</b>
<b>IV</b>	<b>23 (68%)</b>	<b>71 (62%)</b>
<b>Smoking history</b>		
<b>Current/former</b>	<b>21 (62%)</b>	<b>98 (85%)</b>
<b>Never</b>	<b>13 (38%)</b>	<b>17 (15%)</b>
<b>Ad, adenocarcinoma</b>		



Table 5. The number of patients receiving multiple chemotherapies (n=223)			
		Group A ('92-'99)	Group B ('00-'03)
2 <sup>nd</sup> -line	yes	4 (5%)	62 <sup>a</sup> (42%)
	no	70 (95%)	87 (58%)
3 <sup>rd</sup> -line	yes	0 (0%)	22 <sup>b</sup> (15%)
	no	74 (100%)	127 (85%)
4 <sup>th</sup> -line	yes	0 (0%)	9 (6%)
	no	74 (100%)	140 (94%)
a, docetaxel 27; EGFR-TKI 12; platinum-based 12; others 11			
b, EGFR-TKI 14; docetaxel 1; others 7			

**Table 6. Multivariate analysis for survival**

Variables	Category	MST (months)	Univariate	Multivariate	
			<i>p</i>	Risk ratio	95%CI
Age	<70	7.6	0.6031	1.0930	0.815-1.465
	≥70	7.0			
Sex	Female	9.7	0.0012*	1.4060	0.798-2.476
	Male	7.0			
PS	0-1	7.5	0.1509	1.3030	0.783-2.169
	2	4.0			
Histology	Ad	7.5	0.0564	0.8300	0.623-1.106
	non-Ad	6.7			
Stage	≤IIIB	9.3	0.0094*	0.6120	0.524-0.949
	IV	6.8			
Smoking history	(-)	9.2	0.0062*	0.8510	0.634-2.044
	(+)	7.0			
Platinum-doublet	(-)	7.3	0.8551	1.1260	0.829-1.529
	(+)	7.1			
3rd-generation agent	(-)	6.7	0.2715	0.8640	0.596-1.252
	(+)	7.3			
EGFR-TKI	(-)	6.7	<0.0001*	0.7900	0.453-1.379
	(+)	15.0			
Salvage chemotherapy	(-)	5.8	<0.0001*	0.5100	0.335-0.776
	(+)	12.6			

EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; Ad, adenocarcinoma